[{"id":"59201174-86d0-4c21-b519-220173f5e9be","acronym":"ENABLE","url":"https://clinicaltrials.gov/study/NCT04049513","created_at":"2021-01-18T19:51:32.910Z","updated_at":"2024-07-02T16:34:26.420Z","phase":"Phase 1","brief_title":"ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)","source_id_and_acronym":"NCT04049513 - ENABLE","lead_sponsor":"Malaghan Institute of Medical Research","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • WZTL-002 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/11/2019","start_date":" 10/11/2019","primary_txt":" Primary completion: 06/12/2024","primary_completion_date":" 06/12/2024","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"}]